AOn Monday the big crowd in Rhineland-Palatinate was for the US company Eli Lilly. Chancellor Olaf Scholz, Health Minister Karl Lauterbach and Prime Minister Malu Dreyer came to celebrate the symbolic groundbreaking for the Americans' new production facility in Alzey. The pharmaceutical giant is building a new plant there for 2.3 billion euros without German subsidies, which will produce, among other things, the diet preparation Mounjaro from 2027.
The drug, which is used against diabetes and obesity, belongs to one of the most exciting drug classes currently known, the so-called weight loss injections. With the Danish Novo Nordisk, Eli Lilly dominates this market, which experts attest to have a potential of more than 100 billion dollars. The two companies were the first to come onto the market with the GLP-1 receptor antagonists behind the appetite suppressants. But they are not the only companies working on it. Boehringer Ingelheim is also developing a product of this class, just half an hour's drive from Alzey.
#Boehringer #Ingelheim #shake #diet #market